To evaluate the safety profile and tolerabilty of Doxil in combination with the MDR inhibitor, PSC 833 in the treatment of AIS-related Kaposi's sarcoma. To determine the maximum tolerated dose of Doxil in comb. w PSC 833. To determine the dose-limiting toxicity of Doxil in comb. w PSC 833. To study the effects of PSC 833 on Doxil pharmacokinetics. To confirm MDR expressio with immunohistochemistry and functioally, with Tcsestamibi.
Showing the most recent 10 out of 497 publications